Breaking News

Thursday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	JPMorgan to hold a virtual conference » 04:55 01/14/21 01/14 04:55 01/14/21 04:55 ABMD Abiomed $323.77 / -1.24 (-0.38%) , AGIO Agios Pharmaceuticals $46.48 / -0.06 (-0.13%) , AHCO AdaptHealth $36.94 / +0.165 (+0.45%) , BCAB BioAtla $44.92 / +3.54 (+8.55%) , NXGN NextGen Healthcare $21.27 / +0.79 (+3.86%) , OLMA Olema Oncology $41.90 / -0.07 (-0.17%) , PCRX Pacira $73.50 / +0.39 (+0.53%) , BIIB Biogen $266.71 / -0.81 (-0.30%) , ESPR Esperion $26.94 / -3.335 (-11.02%) , EXEL Exelixis $24.38 / -0.845 (-3.35%) , HQY HealthEquity $75.73 / -0.25 (-0.33%) , MORF Morphic Holding $30.30 / +0.29 (+0.97%) , NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) , SRPT Sarepta $87.22 / +0.03 (+0.03%) , SHC Sotera Health $25.01 / -0.19 (-0.75%) , RVNC Revance $29.02 / -0.45 (-1.53%) , RUBY Rubius Therapeutics $8.89 / -0.28 (-3.05%) , ZYME Zymeworks $52.97 / -0.87 (-1.62%) 39th Annual Healthcare… 39th Annual Healthcare Virtual Conference will be held on January 11-14. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZYME SRPT SHC RVNC RUBY PCRX NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $52.97 / -0.87 (-1.62%) 12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo SRPT Sarepta $87.22 / +0.03 (+0.03%) 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint SHC Sotera Health $25.01 / -0.19 (-0.75%) 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility RVNC Revance $29.02 / -0.45 (-1.53%) 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues RUBY Rubius Therapeutics $8.89 / -0.28 (-3.05%) 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause PCRX Pacira $73.50 / +0.39 (+0.53%) 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' MORF Morphic Holding $30.30 / +0.29 (+0.97%) 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 HQY HealthEquity $75.73 / -0.25 (-0.33%) 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 EXEL Exelixis $24.38 / -0.845 (-3.35%) 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact ESPR Esperion $26.94 / -3.335 (-11.02%) 01/13/21 Esperion sees FY21 operating expenses approximately $320M-$340M 01/13/21 Esperion sees Q4 U.S. net product revenue $8M-$8.5M 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave BIIB Biogen $266.71 / -0.81 (-0.30%) 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products AHCO AdaptHealth $36.94 / +0.165 (+0.45%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals $46.48 / -0.06 (-0.13%) 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 ABMD Abiomed $323.77 / -1.24 (-0.38%) 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set ABMD AGIO AHCO BCAB NXGN OLMA PCRX BIIB ESPR EXEL HQY MORF NNOX SRPT SHC RVNC RUBY ZYME ABMD Abiomed $323.77 / -1.24 (-0.38%) 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals $46.48 / -0.06 (-0.13%) 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays AHCO AdaptHealth $36.94 / +0.165 (+0.45%) 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink BCAB BioAtla $44.92 / +3.54 (+8.55%) 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG NXGN NextGen Healthcare $21.27 / +0.79 (+3.86%) 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank OLMA Olema Oncology $41.90 / -0.07 (-0.17%) 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen PCRX Pacira $73.50 / +0.39 (+0.53%) 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland BIIB Biogen $266.71 / -0.81 (-0.30%) 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James ESPR Esperion $26.94 / -3.335 (-11.02%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi EXEL Exelixis $24.38 / -0.845 (-3.35%) 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler HQY HealthEquity $75.73 / -0.25 (-0.33%) 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan MORF Morphic Holding $30.30 / +0.29 (+0.97%) 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg SRPT Sarepta $87.22 / +0.03 (+0.03%) 01/12/21 Citi Sarepta downgraded to Neutral from Buy at Citi 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS SHC Sotera Health $25.01 / -0.19 (-0.75%) 01/13/21 Baird Sotera Health initiated with an Outperform at Baird 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies RVNC Revance $29.02 / -0.45 (-1.53%) 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays RUBY Rubius Therapeutics $8.89 / -0.28 (-3.05%) 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation ZYME Zymeworks $52.97 / -0.87 (-1.62%) 01/12/21 SVB Leerink Zymeworks price target raised to $66 from $45 at SVB Leerink 01/12/21 Wells Fargo Zymeworks price target raised to $71 from $58 at Wells Fargo 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations ZYME SRPT SHC RVNC RUBY PCRX NXGN NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $52.97 / -0.87 (-1.62%) 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) SRPT Sarepta $87.22 / +0.03 (+0.03%) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) SHC Sotera Health $25.01 / -0.19 (-0.75%) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M RVNC Revance $29.02 / -0.45 (-1.53%) 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) RUBY Rubius Therapeutics $8.89 / -0.28 (-3.05%) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) PCRX Pacira $73.50 / +0.39 (+0.53%) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M NXGN NextGen Healthcare $21.27 / +0.79 (+3.86%) 01/13/21 NextGen Healthcare sees FY21 EPS 92c-98c, consensus 89c 01/13/21 NextGen Healthcare sees Q3 EPS 24c-26c, consensus 19c 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) MORF Morphic Holding $30.30 / +0.29 (+0.97%) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) HQY HealthEquity $75.73 / -0.25 (-0.33%) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 EXEL Exelixis $24.38 / -0.845 (-3.35%) 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c ESPR Esperion $26.94 / -3.335 (-11.02%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 BIIB Biogen $266.71 / -0.81 (-0.30%) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open AHCO AdaptHealth $36.94 / +0.165 (+0.45%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals $46.48 / -0.06 (-0.13%) 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) ABMD Abiomed $323.77 / -1.24 (-0.38%) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c 06 Jan 15 Dec 16 Dec 19 Nov 20 Nov 03 Sep 21 Aug 09 Jul 01 Jul 12 Feb 23 Jan NNOX BIIB NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 09/22/20 Muddy Waters joins Citron in shorting Nano-X Imaging 09/17/20 Tilson says Citron's Left right about Nano-X Imaging, 'stock is worthless' BIIB Biogen $266.71 / -0.81 (-0.30%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says SRPT RVNC OLMA NNOX HQY ESPR BIIB BCAB SRPT Sarepta $87.22 / +0.03 (+0.03%) 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Pre-market Movers RVNC Revance $29.02 / -0.45 (-1.53%) 11/09/20 Fly Intel: After-Hours Movers OLMA Olema Oncology $41.90 / -0.07 (-0.17%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 10/02/20 Fly Intel: Wall Street's top stories for Friday 10/02/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Pre-market Movers HQY HealthEquity $75.73 / -0.25 (-0.33%) 09/08/20 Fly Intel: After-Hours Movers ESPR Esperion $26.94 / -3.335 (-11.02%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street BIIB Biogen $266.71 / -0.81 (-0.30%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street BCAB BioAtla $44.92 / +3.54 (+8.55%) 12/20/20 Opening Day: Upstart, Wish make trading debuts 01/14/21 39th Annual Healthcare Virtual Conference 01/14/21 Biogen Business Update Webinar 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/15/21 Zymeworks - ZYME 01/27/21 Zymeworks - ZYME 01/27/21 NextGen Healthcare - NXGN 02/03/21 Biogen - BIIB 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 02/25/21 PDUFA Date for Casimersen 03/07/21 PDUFA Date for Aducanumab 03/22/21 PDUFA Date for EXPAREL BIIB BIIB Biogen $266.71 / -0.81 (-0.30%) 09/15/20 Alexion strength attributed to takeover speculation NNOX HQY ESPR BIIB AHCO NNOX Nano-X Imaging $54.30 / +2.66 (+5.15%) 01/04/21 Largest borrow rate increases among liquid names 10/07/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/23/20 Four new option listings and one option delisting on September 23rd HQY HealthEquity $75.73 / -0.25 (-0.33%) 09/08/20 HealthEquity options imply 10.3% move in share price post-earnings ESPR Esperion $26.94 / -3.335 (-11.02%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names BIIB Biogen $266.71 / -0.81 (-0.30%) 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th AHCO AdaptHealth $36.94 / +0.165 (+0.45%) 11/25/20 new option listings on November 25th

Wednesday
Conference/Events	JPMorgan to hold a virtual conference » 04:55 01/13/21 01/13 04:55 01/13/21 04:55 ABMD Abiomed $324.65 / +0.28 (+0.09%) , AGIO Agios Pharmaceuticals $46.54 / -0.19 (-0.41%) , AHCO AdaptHealth $36.78 / -0.405 (-1.09%) , BCAB BioAtla $41.38 / +1.38 (+3.45%) , NXGN NextGen Healthcare $20.50 / +0.89 (+4.54%) , OLMA Olema Oncology $41.97 / +0.84 (+2.04%) , PCRX Pacira $73.11 / +1.46 (+2.04%) , BIIB Biogen $267.44 / -0.13 (-0.05%) , ESPR Esperion $30.28 / -1.01 (-3.23%) , EXEL Exelixis $25.23 / +1.1 (+4.56%) , HQY HealthEquity $75.95 / +1.83 (+2.47%) , MORF Morphic Holding $30.12 / +0.27 (+0.90%) , NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) , SRPT Sarepta $87.32 / -2.46 (-2.74%) , SHC Sotera Health $25.20 / -0.39 (-1.52%) , RVNC Revance $29.47 / +0.46 (+1.59%) , RUBY Rubius Therapeutics $9.16 / +0.12 (+1.33%) , ZYME Zymeworks $53.99 / -2.49 (-4.41%) 39th Annual Healthcare… 39th Annual Healthcare Virtual Conference will be held on January 11-14. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZYME SRPT SHC RVNC RUBY PCRX NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $53.99 / -2.49 (-4.41%) 12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo SRPT Sarepta $87.32 / -2.46 (-2.74%) 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending SHC Sotera Health $25.20 / -0.39 (-1.52%) 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility RVNC Revance $29.47 / +0.46 (+1.59%) 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues RUBY Rubius Therapeutics $9.16 / +0.12 (+1.33%) 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause PCRX Pacira $73.11 / +1.46 (+2.04%) 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' MORF Morphic Holding $30.12 / +0.27 (+0.90%) 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 HQY HealthEquity $75.95 / +1.83 (+2.47%) 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 EXEL Exelixis $25.23 / +1.1 (+4.56%) 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact ESPR Esperion $30.28 / -1.01 (-3.23%) 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets BIIB Biogen $267.44 / -0.13 (-0.05%) 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products AHCO AdaptHealth $36.78 / -0.405 (-1.09%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals $46.54 / -0.19 (-0.41%) 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 ABMD Abiomed $324.65 / +0.28 (+0.09%) 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set ABMD AGIO AHCO BCAB NXGN OLMA PCRX BIIB ESPR EXEL HQY MORF NNOX SRPT SHC RVNC RUBY ZYME ABMD Abiomed $324.65 / +0.28 (+0.09%) 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals $46.54 / -0.19 (-0.41%) 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays AHCO AdaptHealth $36.78 / -0.405 (-1.09%) 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink BCAB BioAtla $41.38 / +1.38 (+3.45%) 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG NXGN NextGen Healthcare $20.50 / +0.89 (+4.54%) 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank OLMA Olema Oncology $41.97 / +0.84 (+2.04%) 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen PCRX Pacira $73.11 / +1.46 (+2.04%) 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland BIIB Biogen $267.44 / -0.13 (-0.05%) 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James ESPR Esperion $30.28 / -1.01 (-3.23%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi EXEL Exelixis $25.23 / +1.1 (+4.56%) 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler HQY HealthEquity $75.95 / +1.83 (+2.47%) 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan MORF Morphic Holding $30.12 / +0.27 (+0.90%) 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg SRPT Sarepta $87.32 / -2.46 (-2.74%) 01/12/21 Citi Sarepta downgraded to Neutral from Buy at Citi 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS SHC Sotera Health $25.20 / -0.39 (-1.52%) 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi RVNC Revance $29.47 / +0.46 (+1.59%) 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays RUBY Rubius Therapeutics $9.16 / +0.12 (+1.33%) 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation ZYME Zymeworks $53.99 / -2.49 (-4.41%) 01/12/21 SVB Leerink Zymeworks price target raised to $66 from $45 at SVB Leerink 01/12/21 Wells Fargo Zymeworks price target raised to $71 from $58 at Wells Fargo 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations ZYME SRPT SHC RVNC RUBY PCRX NXGN NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $53.99 / -2.49 (-4.41%) 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) SRPT Sarepta $87.32 / -2.46 (-2.74%) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) SHC Sotera Health $25.20 / -0.39 (-1.52%) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M RVNC Revance $29.47 / +0.46 (+1.59%) 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) RUBY Rubius Therapeutics $9.16 / +0.12 (+1.33%) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) PCRX Pacira $73.11 / +1.46 (+2.04%) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M NXGN NextGen Healthcare $20.50 / +0.89 (+4.54%) 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) MORF Morphic Holding $30.12 / +0.27 (+0.90%) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) HQY HealthEquity $75.95 / +1.83 (+2.47%) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 EXEL Exelixis $25.23 / +1.1 (+4.56%) 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c ESPR Esperion $30.28 / -1.01 (-3.23%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 BIIB Biogen $267.44 / -0.13 (-0.05%) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open AHCO AdaptHealth $36.78 / -0.405 (-1.09%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals $46.54 / -0.19 (-0.41%) 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) ABMD Abiomed $324.65 / +0.28 (+0.09%) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c 06 Jan 15 Dec 16 Dec 19 Nov 20 Nov 03 Sep 21 Aug 09 Jul 01 Jul 12 Feb 23 Jan NNOX BIIB NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 09/22/20 Muddy Waters joins Citron in shorting Nano-X Imaging 09/17/20 Tilson says Citron's Left right about Nano-X Imaging, 'stock is worthless' BIIB Biogen $267.44 / -0.13 (-0.05%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says SRPT RVNC OLMA NNOX HQY ESPR BIIB BCAB SRPT Sarepta $87.32 / -2.46 (-2.74%) 01/12/21 NIO downgrade, Wells Fargo upgrade among today's top calls on Wall Street 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Pre-market Movers RVNC Revance $29.47 / +0.46 (+1.59%) 11/09/20 Fly Intel: After-Hours Movers OLMA Olema Oncology $41.97 / +0.84 (+2.04%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 10/02/20 Fly Intel: Wall Street's top stories for Friday 10/02/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Pre-market Movers HQY HealthEquity $75.95 / +1.83 (+2.47%) 09/08/20 Fly Intel: After-Hours Movers ESPR Esperion $30.28 / -1.01 (-3.23%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street BIIB Biogen $267.44 / -0.13 (-0.05%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street BCAB BioAtla $41.38 / +1.38 (+3.45%) 12/20/20 Opening Day: Upstart, Wish make trading debuts 01/14/21 39th Annual Healthcare Virtual Conference 01/14/21 Biogen Business Update Webinar 01/15/21 Zymeworks - ZYME 01/27/21 Zymeworks - ZYME 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 02/25/21 PDUFA Date for Casimersen 03/07/21 PDUFA Date for Aducanumab 03/22/21 PDUFA Date for EXPAREL BIIB BIIB Biogen $267.44 / -0.13 (-0.05%) 09/15/20 Alexion strength attributed to takeover speculation NNOX HQY ESPR BIIB AHCO NNOX Nano-X Imaging $51.61 / +0.22 (+0.43%) 01/04/21 Largest borrow rate increases among liquid names 10/07/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/23/20 Four new option listings and one option delisting on September 23rd HQY HealthEquity $75.95 / +1.83 (+2.47%) 09/08/20 HealthEquity options imply 10.3% move in share price post-earnings ESPR Esperion $30.28 / -1.01 (-3.23%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names BIIB Biogen $267.44 / -0.13 (-0.05%) 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th AHCO AdaptHealth $36.78 / -0.405 (-1.09%) 11/25/20 new option listings on November 25th

Tuesday
Conference/Events	JPMorgan to hold a virtual conference » 04:55 01/12/21 01/12 04:55 01/12/21 04:55 ABMD Abiomed $324.31 / +0.31 (+0.10%) , AGIO Agios Pharmaceuticals $46.71 / +0.81 (+1.76%) , AHCO AdaptHealth $37.18 / -1.06 (-2.77%) , BCAB BioAtla $40.00 / +1.79 (+4.68%) , NXGN NextGen Healthcare $19.60 / -0.26 (-1.31%) , OLMA Olema Oncology $41.65 / -0.84 (-1.98%) , PCRX Pacira $71.65 / +1.58 (+2.25%) , BIIB Biogen $267.53 / +15.17 (+6.01%) , ESPR Esperion $31.29 / +0.25 (+0.81%) , EXEL Exelixis $24.13 / +1.3 (+5.69%) , HQY HealthEquity $74.12 / -1.03 (-1.37%) , MORF Morphic Holding $29.83 / -0.64 (-2.10%) , NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) , SRPT Sarepta $89.78 / +7.48 (+9.09%) , SHC Sotera Health $25.59 / +0.59 (+2.36%) , RVNC Revance $29.00 / -0.41 (-1.39%) , RUBY Rubius Therapeutics $9.03 / -0.47 (-4.95%) , ZYME Zymeworks $56.48 / -0.45 (-0.79%) 39th Annual Healthcare… 39th Annual Healthcare Virtual Conference will be held on January 11-14. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZYME SRPT SHC RVNC RUBY PCRX NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $56.48 / -0.45 (-0.79%) 12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo SRPT Sarepta $89.78 / +7.48 (+9.09%) 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending SHC Sotera Health $25.59 / +0.59 (+2.36%) 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility RVNC Revance $29.00 / -0.41 (-1.39%) 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues RUBY Rubius Therapeutics $9.03 / -0.47 (-4.95%) 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause PCRX Pacira $71.65 / +1.58 (+2.25%) 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' MORF Morphic Holding $29.83 / -0.64 (-2.10%) 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 HQY HealthEquity $74.12 / -1.03 (-1.37%) 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 EXEL Exelixis $24.13 / +1.3 (+5.69%) 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact ESPR Esperion $31.29 / +0.25 (+0.81%) 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets BIIB Biogen $267.53 / +15.17 (+6.01%) 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products AHCO AdaptHealth $37.18 / -1.06 (-2.77%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals $46.71 / +0.81 (+1.76%) 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 ABMD Abiomed $324.31 / +0.31 (+0.10%) 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set ABMD AGIO AHCO BCAB NXGN OLMA PCRX BIIB ESPR EXEL HQY MORF NNOX SRPT SHC RVNC RUBY ZYME ABMD Abiomed $324.31 / +0.31 (+0.10%) 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals $46.71 / +0.81 (+1.76%) 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays AHCO AdaptHealth $37.18 / -1.06 (-2.77%) 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink BCAB BioAtla $40.00 / +1.79 (+4.68%) 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG NXGN NextGen Healthcare $19.60 / -0.26 (-1.31%) 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank OLMA Olema Oncology $41.65 / -0.84 (-1.98%) 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen PCRX Pacira $71.65 / +1.58 (+2.25%) 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland BIIB Biogen $267.53 / +15.17 (+6.01%) 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James ESPR Esperion $31.29 / +0.25 (+0.81%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi EXEL Exelixis $24.13 / +1.3 (+5.69%) 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler HQY HealthEquity $74.12 / -1.03 (-1.37%) 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan MORF Morphic Holding $29.83 / -0.64 (-2.10%) 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg SRPT Sarepta $89.78 / +7.48 (+9.09%) 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 01/08/21 Chardan Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan SHC Sotera Health $25.59 / +0.59 (+2.36%) 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi RVNC Revance $29.00 / -0.41 (-1.39%) 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays RUBY Rubius Therapeutics $9.03 / -0.47 (-4.95%) 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation ZYME Zymeworks $56.48 / -0.45 (-0.79%) 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 08/06/20 SVB Leerink SVB Leerink bullish on Zymeworks, initiates with an Outperform 08/06/20 SVB Leerink Zymeworks initiated with an Outperform at SVB Leerink ZYME SRPT SHC RVNC RUBY PCRX NXGN NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $56.48 / -0.45 (-0.79%) 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) SRPT Sarepta $89.78 / +7.48 (+9.09%) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) SHC Sotera Health $25.59 / +0.59 (+2.36%) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M RVNC Revance $29.00 / -0.41 (-1.39%) 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) RUBY Rubius Therapeutics $9.03 / -0.47 (-4.95%) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) PCRX Pacira $71.65 / +1.58 (+2.25%) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M NXGN NextGen Healthcare $19.60 / -0.26 (-1.31%) 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) MORF Morphic Holding $29.83 / -0.64 (-2.10%) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) HQY HealthEquity $74.12 / -1.03 (-1.37%) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 EXEL Exelixis $24.13 / +1.3 (+5.69%) 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c ESPR Esperion $31.29 / +0.25 (+0.81%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 BIIB Biogen $267.53 / +15.17 (+6.01%) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open AHCO AdaptHealth $37.18 / -1.06 (-2.77%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals $46.71 / +0.81 (+1.76%) 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) ABMD Abiomed $324.31 / +0.31 (+0.10%) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c 06 Jan 15 Dec 16 Dec 19 Nov 20 Nov 03 Sep 21 Aug 09 Jul 01 Jul 12 Feb 23 Jan NNOX BIIB NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 09/22/20 Muddy Waters joins Citron in shorting Nano-X Imaging 09/17/20 Tilson says Citron's Left right about Nano-X Imaging, 'stock is worthless' BIIB Biogen $267.53 / +15.17 (+6.01%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says SRPT RVNC OLMA NNOX HQY ESPR BIIB BCAB SRPT Sarepta $89.78 / +7.48 (+9.09%) 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Pre-market Movers 01/07/21 Fly Intel: After-Hours Movers RVNC Revance $29.00 / -0.41 (-1.39%) 11/09/20 Fly Intel: After-Hours Movers OLMA Olema Oncology $41.65 / -0.84 (-1.98%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 10/02/20 Fly Intel: Wall Street's top stories for Friday 10/02/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Pre-market Movers HQY HealthEquity $74.12 / -1.03 (-1.37%) 09/08/20 Fly Intel: After-Hours Movers ESPR Esperion $31.29 / +0.25 (+0.81%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street BIIB Biogen $267.53 / +15.17 (+6.01%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street BCAB BioAtla $40.00 / +1.79 (+4.68%) 12/20/20 Opening Day: Upstart, Wish make trading debuts 01/14/21 39th Annual Healthcare Virtual Conference 01/14/21 Biogen Business Update Webinar 01/15/21 Zymeworks - ZYME 01/27/21 Zymeworks - ZYME 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 02/25/21 PDUFA Date for Casimersen 03/07/21 PDUFA Date for Aducanumab 03/22/21 PDUFA Date for EXPAREL BIIB BIIB Biogen $267.53 / +15.17 (+6.01%) 09/15/20 Alexion strength attributed to takeover speculation NNOX HQY ESPR BIIB AHCO NNOX Nano-X Imaging $51.39 / -1.625 (-3.07%) 01/04/21 Largest borrow rate increases among liquid names 10/07/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/23/20 Four new option listings and one option delisting on September 23rd HQY HealthEquity $74.12 / -1.03 (-1.37%) 09/08/20 HealthEquity options imply 10.3% move in share price post-earnings ESPR Esperion $31.29 / +0.25 (+0.81%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names BIIB Biogen $267.53 / +15.17 (+6.01%) 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th AHCO AdaptHealth $37.18 / -1.06 (-2.77%) 11/25/20 new option listings on November 25th

Over a week ago
Conference/Events	JPMorgan to hold a virtual conference » 09:44 01/11/21 01/11 09:44 01/11/21 09:44 ABMD Abiomed $324.00 / + (+0.00%) , AGIO Agios Pharmaceuticals $45.85 / -0.05 (-0.11%) , AHCO AdaptHealth $38.24 / + (+0.00%) , BCAB BioAtla $38.22 / +0.01 (+0.03%) , NXGN NextGen Healthcare $19.92 / +0.06 (+0.30%) , OLMA Olema Oncology $42.48 / -0.01 (-0.02%) , PCRX Pacira $70.03 / -0.04 (-0.06%) , BIIB Biogen $252.57 / +0.21 (+0.08%) , ESPR Esperion $31.04 / + (+0.00%) , EXEL Exelixis $22.84 / +0.01 (+0.04%) , HQY HealthEquity $75.22 / +0.07 (+0.09%) , MORF Morphic Holding $30.47 / + (+0.00%) , NNOX Nano-X Imaging $53.02 / + (+0.00%) , SRPT Sarepta $82.30 / + (+0.00%) , SHC Sotera Health $25.00 / + (+0.00%) , RVNC Revance $29.41 / + (+0.00%) , RUBY Rubius Therapeutics $9.50 / + (+0.00%) , ZYME Zymeworks $56.95 / +0.02 (+0.04%) 39th Annual Healthcare… 39th Annual Healthcare Virtual Conference will be held on January 11-14. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZYME SRPT SHC RVNC RUBY PCRX NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $56.95 / +0.02 (+0.04%) 12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo SRPT Sarepta $82.30 / + (+0.00%) 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending SHC Sotera Health $25.00 / + (+0.00%) 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility RVNC Revance $29.41 / + (+0.00%) 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues RUBY Rubius Therapeutics $9.50 / + (+0.00%) 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause PCRX Pacira $70.03 / -0.04 (-0.06%) 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M NNOX Nano-X Imaging $53.02 / + (+0.00%) 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' MORF Morphic Holding $30.47 / + (+0.00%) 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 HQY HealthEquity $75.22 / +0.07 (+0.09%) 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 EXEL Exelixis $22.84 / +0.01 (+0.04%) 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact ESPR Esperion $31.04 / + (+0.00%) 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets BIIB Biogen $252.57 / +0.21 (+0.08%) 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 12/22/20 LogicBio Therapeutics names Cecilia Jones as CFO, succeeding Matthias Jaffe AHCO AdaptHealth $38.24 / + (+0.00%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals $45.85 / -0.05 (-0.11%) 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 ABMD Abiomed $324.00 / + (+0.00%) 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set ABMD AGIO AHCO BCAB NXGN OLMA PCRX BIIB ESPR EXEL HQY MORF NNOX SRPT SHC RVNC RUBY ZYME ABMD Abiomed $324.00 / + (+0.00%) 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals $45.85 / -0.05 (-0.11%) 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays AHCO AdaptHealth $38.24 / + (+0.00%) 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink BCAB BioAtla $38.22 / +0.01 (+0.03%) 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG NXGN NextGen Healthcare $19.92 / +0.06 (+0.30%) 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank OLMA Olema Oncology $42.48 / -0.01 (-0.02%) 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen PCRX Pacira $70.03 / -0.04 (-0.06%) 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland BIIB Biogen $252.57 / +0.21 (+0.08%) 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 12/01/20 Citi Sage Therapeutics price target lowered to $93 from $100 at Citi ESPR Esperion $31.04 / + (+0.00%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi EXEL Exelixis $22.84 / +0.01 (+0.04%) 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler HQY HealthEquity $75.22 / +0.07 (+0.09%) 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan MORF Morphic Holding $30.47 / + (+0.00%) 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital NNOX Nano-X Imaging $53.02 / + (+0.00%) 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg SRPT Sarepta $82.30 / + (+0.00%) 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 01/08/21 Chardan Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan 01/08/21 JPMorgan Sarepta downgraded to Underweight from Overweight at JPMorgan SHC Sotera Health $25.00 / + (+0.00%) 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi RVNC Revance $29.41 / + (+0.00%) 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays RUBY Rubius Therapeutics $9.50 / + (+0.00%) 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation ZYME Zymeworks $56.95 / +0.02 (+0.04%) 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 08/06/20 SVB Leerink SVB Leerink bullish on Zymeworks, initiates with an Outperform 08/06/20 SVB Leerink Zymeworks initiated with an Outperform at SVB Leerink ZYME SRPT SHC RVNC RUBY PCRX NXGN NNOX MORF HQY EXEL ESPR BIIB AHCO AGIO ABMD ZYME Zymeworks $56.95 / +0.02 (+0.04%) 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) SRPT Sarepta $82.30 / + (+0.00%) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) SHC Sotera Health $25.00 / + (+0.00%) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M RVNC Revance $29.41 / + (+0.00%) 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) RUBY Rubius Therapeutics $9.50 / + (+0.00%) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) PCRX Pacira $70.03 / -0.04 (-0.06%) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M NXGN NextGen Healthcare $19.92 / +0.06 (+0.30%) 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c NNOX Nano-X Imaging $53.02 / + (+0.00%) 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) MORF Morphic Holding $30.47 / + (+0.00%) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) HQY HealthEquity $75.22 / +0.07 (+0.09%) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 EXEL Exelixis $22.84 / +0.01 (+0.04%) 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c ESPR Esperion $31.04 / + (+0.00%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 BIIB Biogen $252.57 / +0.21 (+0.08%) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open AHCO AdaptHealth $38.24 / + (+0.00%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals $45.85 / -0.05 (-0.11%) 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) ABMD Abiomed $324.00 / + (+0.00%) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c 06 Jan 15 Dec 16 Dec 19 Nov 20 Nov 03 Sep 21 Aug 09 Jul 01 Jul 12 Feb 23 Jan NNOX BIIB NNOX Nano-X Imaging $53.02 / + (+0.00%) 09/22/20 Muddy Waters joins Citron in shorting Nano-X Imaging 09/17/20 Tilson says Citron's Left right about Nano-X Imaging, 'stock is worthless' BIIB Biogen $252.57 / +0.21 (+0.08%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says SRPT RVNC OLMA NNOX HQY ESPR BIIB BCAB SRPT Sarepta $82.30 / + (+0.00%) 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Pre-market Movers 01/07/21 Fly Intel: After-Hours Movers RVNC Revance $29.41 / + (+0.00%) 11/09/20 Fly Intel: After-Hours Movers OLMA Olema Oncology $42.48 / -0.01 (-0.02%) 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO NNOX Nano-X Imaging $53.02 / + (+0.00%) 10/02/20 Fly Intel: Wall Street's top stories for Friday 10/02/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Wall Street's top stories at midday 09/22/20 Fly Intel: Pre-market Movers HQY HealthEquity $75.22 / +0.07 (+0.09%) 09/08/20 Fly Intel: After-Hours Movers ESPR Esperion $31.04 / + (+0.00%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street BIIB Biogen $252.57 / +0.21 (+0.08%) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers 11/09/20 Fly Intel: Wall Street's top stories for Monday BCAB BioAtla $38.22 / +0.01 (+0.03%) 12/20/20 Opening Day: Upstart, Wish make trading debuts 01/14/21 39th Annual Healthcare Virtual Conference 01/15/21 Zymeworks - ZYME 01/27/21 Zymeworks - ZYME 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 02/25/21 PDUFA Date for Casimersen 03/07/21 PDUFA Date for Aducanumab 03/22/21 PDUFA Date for EXPAREL BIIB BIIB Biogen $252.57 / +0.21 (+0.08%) 09/15/20 Alexion strength attributed to takeover speculation NNOX HQY ESPR BIIB AHCO NNOX Nano-X Imaging $53.02 / + (+0.00%) 01/04/21 Largest borrow rate increases among liquid names 10/07/20 Largest borrow rate increases among liquid names 09/29/20 Largest borrow rate increases among liquid names 09/23/20 Four new option listings and one option delisting on September 23rd HQY HealthEquity $75.22 / +0.07 (+0.09%) 09/08/20 HealthEquity options imply 10.3% move in share price post-earnings ESPR Esperion $31.04 / + (+0.00%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names BIIB Biogen $252.57 / +0.21 (+0.08%) 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th AHCO AdaptHealth $38.24 / + (+0.00%) 11/25/20 new option listings on November 25th
Recommendations	AdaptHealth price target raised to $50 from $39 at Canaccord » 15:08 01/07/21 01/07 15:08 01/07/21 15:08 AHCO AdaptHealth $38.52 / +0.35 (+0.92%) Canaccord analyst Richard… Canaccord analyst Richard Close raised the firm's price target on AdaptHealth to $50 from $39 and keeps a Buy rating on the shares while calling it a focus stock for 2021. In 2021, he expects to see accelerated adoption of disruptive models in healthcare services and expects demand for next generation companies to remain high, Close tells investors. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $38.52 / +0.35 (+0.92%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AHCO AdaptHealth $38.52 / +0.35 (+0.92%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $38.52 / +0.35 (+0.92%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 06 Jan 15 Dec 03 Sep 01 Jul AHCO AdaptHealth $38.52 / +0.35 (+0.92%) 11/25/20 new option listings on November 25th

Syndicate	AdaptHealth 8M share Secondary priced at $33.00 » 06:23 01/06/21 01/06 06:23 01/06/21 06:23 AHCO AdaptHealth $33.87 / -1.91 (-5.34%) Deutsche Bank, Jefferies,… Deutsche Bank, Jefferies, BofA and Truist acted as joint book running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $33.87 / -1.91 (-5.34%) 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AHCO AdaptHealth $33.87 / -1.91 (-5.34%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $33.87 / -1.91 (-5.34%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 06 Jan 15 Dec 03 Sep 01 Jul AHCO AdaptHealth $33.87 / -1.91 (-5.34%) 11/25/20 new option listings on November 25th
Hot Stocks	AdaptHealth falls 5% to $34.00 per share after equity offering 18:54 01/04/21 01/04 18:54 01/04/21 18:54 AHCO AdaptHealth $35.75 / -1.81 (-4.82%) ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 09/21/20 AdaptHealth names Frank Mullen as Chief Accounting Officer AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 15 Dec 03 Sep 01 Jul AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 11/25/20 new option listings on November 25th
Syndicate	AdaptHealth announces offering of 8M shares of Class A common stock » 18:42 01/04/21 01/04 18:42 01/04/21 18:42 AHCO AdaptHealth $35.75 / -1.81 (-4.82%) AdaptHealth announced… AdaptHealth announced that it has commenced an underwritten public offering of 7M shares of its Class A Common Stock, and certain selling stockholders intend to offer and sell an additional 1M shares of the company's Class A Common Stock, subject to market and other conditions. The company intends to use approximately half of the net proceeds of the shares offered by it in this offering, together with senior secured term loan borrowings, the net proceeds from the issuance of unsecured senior notes and cash on hand, to finance the company's previously announced acquisition of AeroCare Holdings, and to pay related fees and expenses, and the remainder for general corporate purposes, which may include future acquisitions and other business opportunities, capital expenditures and working capital. The company will not receive any proceeds from the sale of Class A Common Stock by the selling stockholders. The closing of the AeroCare acquisition is not dependent on the consummation of the offering, and the consummation of the offering is not dependent on the closing of the acquisition. Deutsche Bank Securities, Jefferies, BofA Securities and Truist Securities are acting as lead book-running managers for the offering. Baird, RBC Capital Markets, Stifel, and UBS Investment Bank are acting as joint book-running managers for the offering ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 09/21/20 AdaptHealth names Frank Mullen as Chief Accounting Officer AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 15 Dec 03 Sep 01 Jul AHCO AdaptHealth $35.75 / -1.81 (-4.82%) 11/25/20 new option listings on November 25th

Over a month ago
Syndicate	AdaptHealth 2M share Block Trade priced at $35.15 » 07:41 12/15/20 12/15 07:41 12/15/20 07:41 AHCO AdaptHealth $36.66 / -0.88 (-2.34%) The deal range was… The deal range was $35.15-$35.75. Jefferies acted as sole book running manager for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 09/21/20 AdaptHealth names Frank Mullen as Chief Accounting Officer AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 15 Dec 03 Sep 01 Jul AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 11/25/20 new option listings on November 25th
Syndicate	AdaptHealth 2M share Block Trade; price range $35.15-$35.75 » 17:03 12/14/20 12/14 17:03 12/14/20 17:03 AHCO AdaptHealth $36.66 / -0.88 (-2.34%) Jefferies is acting as… Jefferies is acting as sole book running manager for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 09/21/20 AdaptHealth names Frank Mullen as Chief Accounting Officer AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 12/02/20 RBC Capital AdaptHealth price target raised to $50 from $36 at RBC Capital AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c 03 Sep 01 Jul AHCO AdaptHealth $36.66 / -0.88 (-2.34%) 11/25/20 new option listings on November 25th

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial